Secondary Logo

Institutional members access full text with Ovid®

Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism

Myers, Sara P., MD; Kutcher, Matthew E., MD; Rosengart, Matthew R., MD; Sperry, Jason L., MD; Peitzman, Andrew B., MD; Brown, Joshua B., MD; Neal, Matthew D., MD

Journal of Trauma and Acute Care Surgery: January 2019 - Volume 86 - Issue 1 - p 20–27
doi: 10.1097/TA.0000000000002061
AAST 2018 PODIUM PAPER
Buy
SDC
Editor's Choice

BACKGROUND Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death. However, the risk of venous thromboembolism (VTE) has been incompletely explored. Previous studies investigating the effect of TXA on VTE vary in their findings. We performed a propensity matched analysis to investigate the association between TXA and VTE following trauma, hypothesizing that TXA is an independent risk factor for VTE.

METHODS This retrospective study queried trauma patients presenting to a single Level I trauma center from 2012 to 2016. Our primary outcome was composite pulmonary embolism or deep vein thrombosis. Mortality, transfusion, intensive care unit and hospital lengths of stay were secondary outcomes. Propensity matched mixed effects multivariate logistic regression was used to determine adjusted odds ratio (aOR) and 95% confidence intervals (95% CI) of TXA on outcomes of interest, adjusting for prespecified confounders. Competing risks regression assessed subdistribution hazard ratio of VTE after accounting for mortality.

RESULTS Of 21,931 patients, 189 pairs were well matched across propensity score variables (standardized differences <0.2). Median Injury Severity Score was 19 (interquartile range, 12–27) and 14 (interquartile range, 8–22) in TXA and non-TXA groups, respectively (p = 0.19). Tranexamic acid was associated with more than threefold increase in the odds of VTE (aOR, 3.3; 95% CI, 1.3–9.1; p = 0.02). Tranexamic acid was not significantly associated with survival (aOR, 0.86; 95% CI, 0.23–3.25; p = 0.83). Risk of VTE remained elevated in the TXA cohort despite accounting for mortality (subdistribution hazard ratio, 2.42; 95% CI, 1.11–5.29; p = 0.03).

CONCLUSION Tranexamic acid may be an independent risk factor for VTE. Future investigation is needed to identify which patients benefit most from TXA, especially given the risks of this intervention to allow a more individualized treatment approach that maximizes benefits and mitigates potential harms.

LEVEL OF EVIDENCE Therapeutic, level III.

From the Department of General Surgery (S.P.M., M.R.R., J.L.S., A.B.P., J.B.B., M.D.N.), The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and Division of Trauma and Critical Care (M.E.K.), The University of Mississippi Medical Center, Jackson, Mississippi.

Address for reprints: Matthew D. Neal, MD, F1271.2 PUH, 200 Lothrop St, Pittsburgh, PA 15213; email: nealm2@upmc.edu.

This article will be presented as a podium presentation at the 77th Annual Meeting of the AAST and Clinical Congress of Acute Care Surgery and 4th World Trauma Congress, September 26–29, 2018 in San Diego, CA.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.jtrauma.com).

© 2019 Lippincott Williams & Wilkins, Inc.